Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
FIGURE: 1 / 3
Secukinumab Antibody (A02153-40) in ELISA
Anti-Secukinumab Antibody (23E11) (GenScript, A02153-40) blocks Secukinumab binding with Human IL-17A recombinant protein. Coating antigen: Secukinumab 1 µg/mL. IL-17A final concentration: 1 µg/mL. Anti-Secukinumab antibody dilutions start from 30 μg/mL. IC50= 0.654 µg/mL.
Product Details
A02153-40
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1, kappa
Class
Monoclonal
Type
Antibody
Clone
23E11
Immunogen
Secukinumab
Conjugate
Form
Lyophilized
Concentration
0.5 mg/mL
Purification
Protein A
Storage buffer
PBS, pH 7.2
Contains
0.02% sodium azide
Storage conditions
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Shipping conditions
Wet ice
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Competitive ELISA recommended dilution: 5-30 µg/mL
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Target Information
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and pharmaceutical Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support